Drug Compounding Oversight Crimped by FDA Staff Shortages

Sept. 21, 2018, 8:54 PM

Keeping up with the rise in compound drug requests in the face of hundreds of job vacancies within the FDA will be a major priority for the agency next year, an FDA official said Sept. 21.

“If you ask my staff, any unit within CDER, that’s what we need,” Janet Woodcock said about resources to handle compounding pharmacy issues. Woodcock is director of the Center for Drug Evaluation and Research for the Food and Drug Administration.

Roughly 1,000 jobs lie vacant across the FDA, which puts additional strain on the agency in general, but especially among the staff who keep ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.